Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2009-06-01
2011-10-11
Bunner, Bridget E (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S145100, C435S069500, C530S350000, C530S387900, C530S388230, C536S023500
Reexamination Certificate
active
08034337
ABSTRACT:
Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
REFERENCES:
patent: 4634664 (1987-01-01), Oestberg
patent: 4965198 (1990-10-01), Yamasaki et al.
patent: 5034316 (1991-07-01), Weisbart et al.
patent: 5168062 (1992-12-01), Stinski
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5654407 (1997-08-01), Boyle et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5792838 (1998-08-01), Smith et al.
patent: 5795967 (1998-08-01), Aggarwal et al.
patent: 5932188 (1999-08-01), Snow et al.
patent: 5959085 (1999-09-01), Garrone et al.
patent: 6090382 (2000-07-01), Salfeld et al.
patent: 6140470 (2000-10-01), Garen et al.
patent: 2003/0026806 (2003-02-01), Witte et al.
patent: 2003/0040617 (2003-02-01), Rosen et al.
patent: 2003/0232054 (2003-12-01), Tang et al.
patent: 2004/0185514 (2004-09-01), Frostegard
patent: 2005/0054019 (2005-03-01), Michaud et al.
patent: 2005/0147603 (2005-07-01), Smith et al.
patent: 2006/0159775 (2006-07-01), McGrath
patent: 2007/0071675 (2007-03-01), Wu et al.
patent: 2008/0050310 (2008-02-01), Ebens, Jr. et al.
patent: 2009/0123415 (2009-05-01), Simard
patent: 2009/0298096 (2009-12-01), Simard
patent: 2010/0040574 (2010-02-01), Simard
patent: 2010/0068212 (2010-03-01), Simard
patent: 9006371 (1990-06-01), None
patent: 9635719 (1996-11-01), None
patent: 2004100987 (2004-11-01), None
patent: 2007015128 (2007-02-01), None
patent: 2007039552 (2007-04-01), None
patent: 2007132338 (2007-11-01), None
patent: 2007135546 (2007-11-01), None
patent: 2010030979 (2010-03-01), None
Eugui et al. Proc. Natl. Acad. Sc. USA., 1990, vol. 87, pp. 1305-1309.
Immunobiology, Janeway et al., The immune system in health and disease, 3rd edition, 1997, section 3.4 and figure 3.4.
Bendtzen, Klaus et al., High-Avidity Autoantibodies to Cytokines, Trends Immunology Today, May 1998, vol. 19, No. 5 209.
Bendtzen, Klaus et al., Detection of Autoantibodies to Cytokines, Molecular Biotechnology, 2000, vol. 14.
Dardik, Alan et al., Shear stress-stimulated endothelial cells induce smooth muscle cell chemotaxis via platelet-derived growth factor-BB and interleukin-1alpha, Journal of Vascular Surgergy, Feb. 2005, vol. 41:321-331.
Dinarello, Charles A., Modalities for reducing interleukin 1 activity in disease, TiPS, May 1993, vol. 14:155-159.
Dinarello, Charles A. et al., Anticytokine strategies in the treatment of the systemic inflammatory response syndrome, The Journal of the American Medical Association, Apr. 1993, vol. 269, No. 14:1829-1835.
Dinarello, Charles A., Biologic basis for interleukin-1 in disease, BLOOD, Mar. 1996, vol. 87, No. 6:2095-2147.
Dinarello, Charles A., Therapeutic strategies to reduce IL-1 activity in treating local and system inflammation, Current Opinion in Pharmacology, 2004, vol. 4:378-385.
Larrick, James W. et al., Prospects for the therapeutic use of human monoclonal antibodies, Journal of Biological Response Modifiers, 1986, vol. 5:379-393.
Garrone, P. et al., Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1 alpha specific inhibitor, Molecular Immunology, 1996, vol. 33. No. 78:649-658.
Griffiths, Andrew D. et al., Human anti-self antibodies with high specificity from phage display libraries, the EMBO Journal, 1993, vol. 12, No. 2:725-734.
Satoh, H. et al., Characterization of anti-IL-1alpha autoantibodies in the sera from healthy humans, Immunopharmacology, 1994, vol. 27:107-118.
Hansen, M. B. et al., Sex- and age-dependency of IgG auto-antibodies against IL-1alpha in healthy humans, European Journal of Clinical Investigation, 1994, vol. 24:212:218.
Jouvenne, P. et al., High levels of neutralizing autoantibodies against IL-1alpha are associated with a better prognosis in chronic polyarthritis: a follow-up study, Scand. J. Immunol., 1997, vol. 46:413-418.
Lindqvist, E. et al., Prognostic laboratory markers of joint damage in rheumatoid arthritis, Ann Rheum Dis, 2005, vol. 64:196-201.
Ogushi, F. et al., Autoantibodies to IL-1alpha in sera from rapidly progressive idiopathic pulmonary fibrosis, The Journal of Medical Investigation, 2001, vol. 48:181-189.
Ross, Christian, et al., High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG, J. Clin. Invest., May 1995, vol. 95:1974-1978.
Saurat, Jean-Hilaire, et al., Anti-interleukin-1alpoha autoantibodies in humans: Characterization, isotype distribution, and receptor-binding inhibition—Higher frequency in Schnitzler's syndrome (urticaria and macroglobulinemia), J. Allergy Clin. Immunol., Aug. 1991, vol. 88, No. 2:243-256.
Suzuki, Hiroshi et al., Demonstration of Neutralizing Autoantibodies against II-1alpha IN sera from patients with rheumatoid arthritis, The Journal of Immunology, Oct. 1, 1990, vol. 145, No. 7:2140-2146.
Svenson, M. et al., IgG Autoantibodies against Interleuking 1alpha in sera of normal individuals, Scand. J. Immunol., 1989, vol. 29:489-492.
Svenson, M. et al., Binding of Cytokines to Pharmaceutically Prepared Human Immunoglobulin, J. Clin. Invest., Nov. 1993, vol. 92:2533-2539.
Svenson, M. et al., Effects of human anti-IL-1alpha autoantibodies on receptor binding and biological activities of IL-1 alpha, CYTOKINE, Mar. 1992, vol. 4, No. 2:125-133.
Svenson, M. et al., Distribution and characterization of autoantibodies to interleukin 1 alpha in normal human sera, Scand. J. Immunol., 1990, vol. 32:695-701.
Svenson, M. et al., Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations, Blood, Mar. 1998, vol. 91, No. 6:2054-2061.
Svenson, M. et al., Cytokine vaccination: neutralising IL-1alpha autoantibodies induced by immunisation with homologous IL-1alpha, Journal of immunological methods, 2000:1-8.
Waehre et al., Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors, <<circ.ahajournals.org>>, downloaded on Jan. 15, 2008:1966-1972.
Clinton Steven K. et al., Interleukin-1 gene expression in rabbit vascular tissue in vivo, American Journal of Pathology, Apr. 1991, vol. 138, No. 4:1005-1014.
Von Der Thusen, Jan H., et al., Interleukins in atherosclerosis: Molecular pathways and therapeutic potential, Pharmacol Rev, 2003, vol. 55, No. 1:133-166.
Kasahara, T. et al., Preparation and characterization of polyclonal and monoclonal antibodies against human interleukin 1 alpha (IL 1alpha), The Journal of Immunology, Mar. 1987, vol. 138, No. 6:1804-1812.
Merhi-Soussi, F. et al., Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apoliprotein E-knockout mice, Cardiovacular Research, 2006, vol. 66:583-593.
Ross, C. et al., Increased in vivo antibody activity against interferon alpha, interleuking-1alpha, and interleukin-6 after high-dose Ig therapy, Blood, Sep. 1997, vol. 90, No. 6:2376-2380.
Ito, R. et al., Interleukin 1alpha acts as an autocrine growth stimulator for human gastric carcinoma cells, Cancer Research, Sep. 1993, vol. 53:4102-4106.
Shirakawa, F. et al., Autocrine stimulation of interleukin 1alpha in the growth of adult human T-cell leukemia cells, Cancer Rsearch, Mar. 1089, vol. 49:1143-1147.
Apte, Ron N., et al., Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions, European Journal of Cancer, 2006, vol. 42:751-759.
Dinarello, Charles A., The role of interleukin-1 in disease, The New England Journal of Medicine, 1993, vol. 328, No. 2:106-113.
Wake, R. et al., Gender differences in ischemic heart disease, Recent Patents on Cardiovascular Drug Discovery, 2009, vol. 4:234-240.
Mariotti, Massimo et al., Interleukin 1 alpha is a marker of endothelial cellular senescent, Immunity & Ageing, Apr. 2006:1-6.
Niki, Yasuo et al., Membrane-associated IL-1 contributes
Bunner Bridget E
Hamud Fozia
Kim Stanley A.
Xbiotech, Inc.
LandOfFree
Interleukin-1α antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interleukin-1α antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interleukin-1α antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4281145